ArticleJapanese journal of clinical oncology2019
Geriatric Research Policy: Japan Clinical Oncology Group (JCOG) policy.
Article in Japanese journal of clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Limited lymphadenectomy for elderly patient with gastric cancer: a systematic review and meta-analysis.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Pooled it
- Association between financial toxicity and frailty among older patients with cancer: a cross-sectional study using COST and G8.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Survival benefit with lobectomy vs. sublobar resection in octogenarians with clinical stage IA lung cancer.Surgery today · 2026Article
- Tablet Acceptability in Older Outpatients Undergoing Cancer Chemotherapy.Geriatrics (Basel, Switzerland) · 2026Article
- Article
- Article
- Evaluating comorbidity scoring systems for flumatinib therapy in chronic myeloid leukemia: a machine learning and SHAP-based predictive analysis.Frontiers in medicine · 2026Article
- A multicenter prospective observational study for health assessment questionnaires EQ-5D-5L and G8 in unresectable advanced pancreatic cancer treated with first-line gemcitabine plus nab-paclitaxel therapy.International journal of clinical oncology · 2025Observational
- Systemic therapy strategies for elderly patients with gastric cancer.Therapeutic advances in medical oncology · 2025Review
- Appropriate Treatment Intensity for Diffuse Large B-Cell Lymphoma in the Older Population: A Review of the Literature.Hematology reports · 2024Review
- Article
- The landscape of immune therapy in vulnerable patients with advanced non-small cell lung cancer: a narrative review.Translational lung cancer research · 2023Review
- Determinants of Self-Rated Health Disparities among Independent Community-Dwelling Older Adults: An Age-Stratified Analysis.Healthcare (Basel, Switzerland) · 2023Article
- Practical management of older adults with cancer: geriatric oncology in Japan.Japanese journal of clinical oncology · 2022Review
- Article
- Challenges in Geriatric Oncology-A Surgeon's Perspective.Current oncology (Toronto, Ont.) · 2022Review
- What Should We Recommend for Colorectal Cancer Screening in Adults Aged 75 and Older?Current oncology (Toronto, Ont.) · 2021Review
- Prognostic factors in older patients with wild-type epidermal growth factor receptor advanced non-small cell lung cancer: a multicenter retrospective study.Translational lung cancer research · 2021Article
- Indications for pancreaticoduodenectomy affected postoperative outcomes in octogenarians.Annals of gastroenterological surgery · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the rapid aging of Japan's population, clinical research focusing on older patients with cancer is urgently needed. The Japan Clinical Oncology Group (JCOG) has conducted several such clinical trials, but there has been no formal policy for geriatric research. We have therefore established a JCOG policy for geriatric cancer research. We defined the patient selection policy based on treatment tolerance and chronological age. Older patients are categorized into three conceptual groups: 'fit patients' who can undergo the same standard treatment given to younger patients, 'frail patients' for whom best supportive or palliative care is indicated and 'vulnerable patients' who fall between the fit and frail categories. Unmet needs often exist for vulnerable patients. The policy recommends that study endpoints include not only survival but also other endpoints such as physical and cognitive function because the objective of therapy in older patients is not only extended life expectancy but also maintenance of the patient's general condition. In this viewpoint, co-primary or composite endpoints that incorporate geriatric assessment in the study design are often applicable. Study design will differ depending on the study population, clinical question, and treatment. Even for older patients, a randomized clinical trial is still the gold standard when the clinical question asks which treatment is better. An observational study of a broader population is applicable for investigating actual conditions of older patients. This JCOG Geriatric Research Policy includes several practical solutions for various issues in geriatric research. We plan to revise this policy periodically to guide future geriatric research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.